Video

SGLT2 Inhibitors and Risk for Ketoacidosis and Urinary Tract Infections

Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.

Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.

This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.

Related Videos
Pharmacist assisting a patient with pericarditis -- Image credit: Yuri Arcurs/peopleimages.com | stock.adobe.com
3D rendering of multiple myeloma cancer cells | Image Credit: © Сергей Косилко - stock.adobe.com
fda on paper texture - Image credit: Araki Illustrations | stock.adobe.com
Patient receiving diabetes consultation -- Image credit: Syda Productions | stock.adobe.com
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com